These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 28183314)

  • 1. DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
    Fadini GP; Bonora BM; Albiero M; Zaninotto M; Plebani M; Avogaro A
    Cardiovasc Diabetol; 2017 Feb; 16(1):22. PubMed ID: 28183314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes.
    Fadini GP; Bonora BM; Cappellari R; Menegazzo L; Vedovato M; Iori E; Marescotti MC; Albiero M; Avogaro A
    J Clin Endocrinol Metab; 2016 Feb; 101(2):748-56. PubMed ID: 26695864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T; Stirban A; Terjung A; Esmaeili H; Berk A; Thiemann S; Chilton R; von Eynatten M; Marx N
    Cardiovasc Diabetol; 2017 Jan; 16(1):13. PubMed ID: 28109295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy.
    Vickery S; Price CP; John RI; Abbas NA; Webb MC; Kempson ME; Lamb EJ
    Am J Kidney Dis; 2005 Oct; 46(4):610-20. PubMed ID: 16183415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    McGuire DK; Alexander JH; Johansen OE; Perkovic V; Rosenstock J; Cooper ME; Wanner C; Kahn SE; Toto RD; Zinman B; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; Marx N;
    Circulation; 2019 Jan; 139(3):351-361. PubMed ID: 30586723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
    Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum N-terminal Pro-brain Natriuretic Peptide Level is Associated with the Development of Chronic Kidney Diseases in Patients with Type 2 Diabetes.
    Sawada R; Hashimoto Y; Senmaru T; Tanaka M; Ushigome E; Yamazaki M; Fukui M
    Endocr Metab Immune Disord Drug Targets; 2018; 18(6):590-595. PubMed ID: 29697035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.
    Awal HB; Nandula SR; Domingues CC; Dore FJ; Kundu N; Brichacek B; Fakhri M; Elzarki A; Ahmadi N; Safai S; Fosso M; Amdur RL; Sen S
    Cardiovasc Diabetol; 2020 Jun; 19(1):72. PubMed ID: 32493344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in the NT-proBNP/Mature BNP Molar Ratio Precedes Worsening Renal Function in Patients With Acute Heart Failure: A Novel Predictor Candidate for Cardiorenal Syndrome.
    Takahama H; Nishikimi T; Takashio S; Hayashi T; Nagai-Okatani C; Asada T; Fujiwara A; Nakagawa Y; Amano M; Hamatani Y; Okada A; Amaki M; Hasegawa T; Kanzaki H; Nishimura K; Yasuda S; Kangawa K; Anzai T; Minamino N; Izumi C
    J Am Heart Assoc; 2019 Sep; 8(17):e011468. PubMed ID: 31441355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
    Wolsk E; Claggett B; Pfeffer MA; Diaz R; Dickstein K; Gerstein HC; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Køber L
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28554908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship.
    Takase H; Dohi Y
    Eur J Clin Invest; 2014; 44(3):303-8. PubMed ID: 24372567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study.
    Spanaus KS; Kronenberg F; Ritz E; Schlapbach R; Fliser D; Hersberger M; Kollerits B; König P; von Eckardstein A;
    Clin Chem; 2007 Jul; 53(7):1264-72. PubMed ID: 17478561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Value of Natriuretic Peptides in Predicting Time to Dialysis in Stage 4 and 5 Chronic Kidney Disease Patients.
    Sundqvist S; Larson T; Cauliez B; Bauer F; Dumont A; Le Roy F; Hanoy M; Fréguin-Bouilland C; Godin M; Guerrot D
    PLoS One; 2016; 11(8):e0159914. PubMed ID: 27548064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function.
    Jafri L; Kashif W; Tai J; Siddiqui I; Azam I; Shahzad H; Ghani F
    BMC Nephrol; 2013 May; 14():117. PubMed ID: 23725445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function.
    Horii M; Matsumoto T; Uemura S; Sugawara Y; Takitsume A; Ueda T; Nakagawa H; Nishida T; Soeda T; Okayama S; Somekawa S; Ishigami K; Takeda Y; Kawata H; Kawakami R; Saito Y
    J Cardiol; 2013 Jun; 61(6):410-6. PubMed ID: 23618914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial.
    Jarolim P; White WB; Cannon CP; Gao Q; Morrow DA
    Diabetes Care; 2018 Jul; 41(7):1510-1515. PubMed ID: 29848776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.